Pantoprazole produces mixed results for Nycomed
This article was originally published in Scrip
Executive Summary
Pantoprazole (Protonix) proved to be both a boon and blight on Nycomed's financial performance in 2009. The gastro-oesophageal reflux disease treatment struggled to cope with its loss of exclusivity in many key European markets, but still drove growth in Latin America.